site stats

Jcog 9912

http://www.jcog.jp/document/s_9912.pdf Web25 mar 2014 · Background In a phase III study for advanced gastric cancer (AGC), the Japan Clinical Oncology Group (JCOG) 9912 trial, we previously identified the following four prognostic factors—performance ...

Effect of RECIST revision on classification of target lesions and ...

WebSurprisingly, there was an improvement in median survival time from 7 months in JCOG 9205 to 11 months in JCOG 9912. Many newer agents were used, such as TS-1, CPT-11, docetaxel, and paclitaxel, which were absent during the previous study (JCOG 9205). Using these agents as a second-line treatment may cause the improvement of survival. Web20 gen 2015 · Patients and methods The Japan Clinical Oncology Group (JCOG)9912 phase III trial compared irinotecan plus cisplatin and S-1 alone with fluorouracil alone for metastatic gastric cancer, and ... sutherland rd e17 https://dynamiccommunicationsolutions.com

A novel clinical prognostic index for patients with advanced …

Web8 nov 2013 · N Fuse, H Fukuda, Y Yamada, et al.: Updated results of randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) … Web12 apr 2010 · N Fuse, H Fukuda, Y Yamada, etal: Updated results of randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG 9912) J Clin Oncol 27: 15s, 2009 suppl; abstr 4514 Google Scholar Web27 ago 2024 · Interestingly, the modified JCOG prognostic index clearly showed the better stratification compared with the JCOG prognostic index according to survival time after progression following first-line chemotherapy in our cohort (Figure 3 A), with the good (n = 277), moderate (n = 225), and poor (n = 50) risk groups having a median PPS of 9.5, 6.4, … sutherland rd brighton ma

(PDF) Determination of Prognostic Factors in Japanese

Category:Choroidal Metastases From Esophageal Adenocarcinoma …

Tags:Jcog 9912

Jcog 9912

Prognostic factors for PFS in patients with advanced gastric cancer ...

Web4 giu 2024 · 10512 Cogswell Ave, Las Vegas NV, is a Single Family home that contains 1215 sq ft and was built in 1997.It contains 2 bedrooms and 2 bathrooms.This home last … Web20 mag 2009 · 4514 Background: We reported the primary results of JCOG9912 in ASCO 2007. In the planning, this study with 230 patients (pts) per arm had 80% power to demonstrate 10% superiority of CP and non-inferiority with 5% margin (HR=1.16) of S-1 at 6 months in overall survival (OS) and 0.05 study-wise 1-sided alpha. Primary analysis was …

Jcog 9912

Did you know?

Web20 gen 2015 · 180 Background: In advanced gastric cancer (AGC), there are many reports about prognostic factors for overall survival (OS), and we have proposed a prognostic index using four prognostic factors (PS, number of metastatic sites, prior gastrectomy and ALP; Oncologist 2014) based on a phase III trial JCOG 9912 for the first-line treatment (Lancet … Web19 mar 2011 · H1,P1,CY1,M1,再発. 予防的D3郭清は施行すべきでない. 膵への直接浸潤や明らかなNo.11 (脾動脈幹)リンパ節転移を有する症例以外は膵尾側切除を行われない. U領域にかかる進行胃癌ではNo.11 (脾門部)郭清のため脾合併切除は望ましい（議論がある）. 食道浸潤長が3cm ...

Web8 feb 2016 · Patients and methods: The Japan Clinical Oncology Group (JCOG)9912 phase III trial compared irinotecan plus cisplatin and S-1 alone with fluorouracil alone for metastatic gastric cancer, and finally demonstrated the non-inferiority of S-1 alone with respect to overall survival (OS). Webcancer (AGC), the Japan Clinical Oncology Group (JCOG) 9912 trial, we previously identified the following four prognostic factors—performance status C1, number of …

Web2010 Georgia Code TITLE 9 - CIVIL PRACTICE CHAPTER 12 - VERDICT AND JUDGMENT ARTICLE 6 - ENFORCEMENT OF FOREIGN JUDGMENTS § 9-12-132 - … Web16 mar 2016 · In the Japan Clinical Oncology Group (JCOG)9912 trial , no significant differences in median survival time were identified between the 5-FU, capecitabine (CAP) and S-1 regimens. However, subgroup analysis indicated that S-1 and CAP were more efficacious than 5-FU in the treatment of diffuse gastric cancer.

Web25 mar 2014 · Background In a phase III study for advanced gastric cancer (AGC), the Japan Clinical Oncology Group (JCOG) 9912 trial, we previously identified the following …

WebBackground: In advanced gastric cancer (AGC), no globally accepted prognostic scoring system has been developed. Therefore, we explored baseline prognostic factors in Japanese AGC patients using the data from a randomized controlled trial, Japan Clinical Oncology Group (JCOG) 9912, which investigated the efficacy of systemic … sizwe hosmed essential copper 2023sutherland rd melroseWeb8 feb 2016 · Patients and methods: The Japan Clinical Oncology Group (JCOG)9912 phase III trial compared irinotecan plus cisplatin and S-1 alone with fluorouracil alone for … sutherland rd w4Web胃癌 JCOG9912. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Boku N, Yamamoto S, Fukuda … sizwe hosmed edo optionWebThe Japanese Clinical Oncology Group (JCOG) 9912 study is a three-arm, multi-institutional randomized trial to prove superiority of irinotecan plus cisplatin (CPT/cisplatin) over 5-FU and non-inferiority Table 1. Randomized trials using older-generation chemotherapeutic regimens Study Regimen N RR, % Median OS, month P value sutherland real estatehttp://www.jcog.jp/en/publications/giosg.html sizwe hosmed gold ascendWebBackground: In a phase III study for advanced gastric cancer (AGC), the Japan Clinical Oncology Group (JCOG) 9912 trial, we previously identified the following four … sizwe hosmed financials